ProMIS Neurosciences announced its Q3 2026 financial results and reaffirmed that unblinded 12-month topline data from its Phase 1b PRECISE-AD trial for Alzheimer’s drug PMN310 will be available in Q1 2027. PMN310 targets toxic amyloid-beta oligomers and has shown promising safety and biomarker results, with no serious adverse events or ARIA-E incidents reported so far. The company has $44.1 million in cash, expected to fund operations through 2027, and is advancing a subcutaneous formulation of PMN310. Upcoming milestones include full trial data release and FDA engagement in 2027.
ProMIS Neurosciences' recent financial results and trial updates provide context for health-sector market activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 04:11 WIB: out of 150 priced health-sector US stocks, 23 rose and 124 fell today. Notable movers include RLAY at USD 18.16 with a 1-day change of -7.91% and a typical hold time of 34 days, CLPT at USD 8.46 down 7.74% with a typical hold time of 13 days and 100% sell order activity, and NUWE at USD 5.11 down 7.59% with a typical hold time of 33 days and 100% sell order activity.
Siemens reported earnings per share of $1.62 and revenue of $26.28 billion, both exceeding analyst expectations. The company saw record orders and double-digit revenue growth in its smart infrastructure and digital industries units, prompting it to r...
ASUS has introduced a broad ecosystem of AI-ready hardware and software designed for gamers, creators, developers, and enterprises. The ASUS Agent Computer initiative enables users to deploy AI locally, in the cloud, or via hybrid models, offering co...
The global cosmetic peptide synthesis market is projected to grow from $274 million in 2027 to $354.85 million by 2032, with a CAGR of 5.34%. Growth is fueled by rising demand for advanced anti-aging skincare ingredients, increased use of peptide-bas...
Cisco is set to report its fiscal Q1 2027 earnings with a focus on cloud growth and AI demand. Analysts expect revenue around $18.1 billion, operating income of $6.5 billion, and earnings per share of $1.33, reflecting strong year-over-year growth. T...
BASF has agreed to sell its global mining solutions business to SNF, a specialty chemical company based in France, following a strategic review of BASF's Performance Chemicals division. The deal includes BASF's mining chemicals portfolio, production ...
